Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer

Journal of Translational Medicine

Volumn 7, Issue , 2009, Pages

  Honma, Ichiya ^a   Torigoe, Toshihiko ^a   Hirohashi, Yoshihiko ^a   Kitamura, Hiroshi ^a   Sato, Eiji ^a   Masumori, Naoya ^a   Tamura, Yasuaki ^a   Tsukamoto, Taiji ^a   Sato, Noriyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; HLA A24 ANTIGEN; ALPHA-METHYLACYL-COA RACEMASE; EPITOPE; HLA A ANTIGEN; ISOMERASE; PEPTIDE;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME BINDING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AMINO ACID SEQUENCE; ANIMAL; ENZYMOLOGY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; PROSTATE TUMOR; PROTEIN BINDING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; MALE; MOLECULAR SEQUENCE DATA; PEPTIDES; PROSTATIC NEOPLASMS; PROTEIN BINDING; RACEMASES AND EPIMERASES; TISSUE DISTRIBUTION;

EID: 73249124636     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-7-103     Document Type: Article

References (36)

1. Foss FM. Immunologic mechanisms of antitumor activity. Semin Oncol 2002, 29:5-11. 10.1053/sonc.2002.33076, 12068382.
2. Boon T, Coulie PG, Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997, 18:267-268. 10.1016/S0167-5699(97)80020-5, 9190110.
3. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999, 10:281-287. 10.1016/S1074-7613(00)80028-X, 10204484.
4. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, Bruggen P, Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999, 80:219-230. 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S, 9935203.
5. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998, 4:321-327. 10.1038/nm0398-321, 2064864, 9500606.
6. Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, Pihan G, Cai F, Babcook JS, Rathanaswami P, Reed SG, Xu J, Fanger GR. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001, 25:1397-1404. 10.1097/00000478-200111000-00007, 11684956.
7. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. Jama 2002, 287:1662-1670. 10.1001/jama.287.13.1662, 11926890.
8. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002, 62:2220-2226.
9. Amery L, Fransen M, De Nys K, Mannaerts GP, Van Veldhoven PP. Mitochondrial and peroxisomal targeting of 2-methylacyl-CoA racemase in humans. J Lipid Res 2000, 41:1752-1759.
10. Ferdinandusse S, Denis S, L IJ, Dacremont G, Waterham HR, Wanders RJ. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res 2000, 41:1890-1896.
11. Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Mori K, Hayashi A, Yamana H, Shirouzu K, Itoh K. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999, 59:4056-4063.
12. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol 1997, 158:3325-3334.
13. Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, Yamada A, Kikuchi M, Tsuda N, Ohta K, Takamori S, Yamana H, Fujita H, Itoh K. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 2000, 164:2565-2574.
14. Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N, Sato N. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002, 8:1731-1739.
15. Hariu H, Hirohashi Y, Torigoe T, Asanuma H, Hariu M, Tamura Y, Aketa K, Nabeta C, Nakanishi K, Kamiguchi K, Mano Y, Kitamura H, Kobayashi J, Tsukahara T, Shijubo N, Sato N. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Clin Cancer Res 2005, 11:1000-1009.
16. Sato T, Sato N, Takahashi S, Koshiba H, Kikuchi K. Specific cytotoxicity of a long-term cultured T-cell clone on human autologous mammary cancer cells. Cancer Res 1986, 46:4384-4389.
17. Kondo A, Sidney J, Southwood S, del Guercio MF, Appella E, Sakamoto H, Celis E, Grey HM, Chesnut RW, Kubo RT, Sette A. Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. J Immunol 1995, 155:4307-4312.
18. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol 1999, 162:293-306. 10.1016/S0022-5347(05)68543-6, 10411025.
19. Hasui Y, Marutsuka K, Asada Y, Ide H, Nishi S, Osada Y. Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate 1994, 25:91-96. 10.1002/pros.2990250206, 7518599.
20. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995, 154:407-413. 10.1016/S0022-5347(01)67064-2, 7541857.
21. Yokokawa J, Bera TK, Palena C, Cereda V, Remondo C, Gulley JL, Arlen PM, Pastan I, Schlom J, Tsang KY. Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). Int J Cancer 2007, 121:595-605. 10.1002/ijc.22698, 17397028.
22. Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K, Harada M. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immunother 2007, 56:689-698. 10.1007/s00262-006-0216-9, 16937115.
23. Alves PM, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross DA, Miconnet I, Chouaib S, Fizazi K, Soria JC, Lemonnier FA, Kosmatopoulos K. STEAP, a prostate tumor antigen, is a target of human CD8+ T cells. Cancer Immunol Immunother 2006, 55:1515-1523. 10.1007/s00262-006-0165-3, 16622681.
24. Kunju LP, Rubin MA, Chinnaiyan AM, Shah RB. Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. Am J Clin Pathol 2003, 120:737-745. 10.1309/3T3Y0K0TUMYH3WY2, 14608901.
25. Beach R, Gown AM, De Peralta-Venturina MN, Folpe AL, Yaziji H, Salles PG, Grignon DJ, Fanger GR, Amin MB. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 2002, 26:1588-1596. 10.1097/00000478-200212000-00006, 12459625.
26. Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM, Epstein JI. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol 2003, 27:1128-1133. 10.1097/00000478-200308000-00010, 12883245.
27. Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, De Marzo AM, Isaacs WB. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res 2003, 63:7365-7376.
28. Date Y, Kimura A, Kato H, Sasazuki T. DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. Tissue Antigens 1996, 47:93-101. 10.1111/j.1399-0039.1996.tb02520.x, 8851721.
29. Takahashi S, Suzuki S, Takahashi S, Inaguma S, Asamoto M, Shirai T. Differences between latent and clinical prostate carcinomas: lower cell proliferation activity in latent cases. Prostate 2006, 66:211-217. 10.1002/pros.20336, 16173032.
30. Kuefer R, Varambally S, Zhou M, Lucas PC, Loeffler M, Wolter H, Mattfeldt T, Hautmann RE, Gschwend JE, Barrette TR, Dunn RL, Chinnaiyan AM, Rubin MA. alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 2002, 161:841-848. 1867250, 12213712.
31. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995, 46:681-686. 10.1016/S0090-4295(99)80301-X, 7495121.
32. Sharpe JC, Abel PD, Gilbertson JA, Brawn P, Foster CS. Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium. Br J Urol 1994, 74:609-616. discussion 686-687, 10.1111/j.1464-410X.1994.tb09193.x, 7530126.
33. Kitamura H, Torigoe T, Asanuma H, Honma I, Sato N, Tsukamoto T. Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J Urol 2007, 178:692-696. 10.1016/j.juro.2007.03.109, 17574613.
34. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002, 3:999-1005. 10.1038/ni1102-999, 1508168, 12407407.
35. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 2004, 53:904-910. 10.1007/s00262-004-0517-9, 15069585.
36. Bubenik J. MHC class I down-regulation: tumour escape From immune surveillance?. Int J Oncol 2004, 25:487-491.